Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2025-01-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
第五届董事会提名委员会关于独立董事候选人任职资格的审查意见
Board/Management Information Classification · 100% confidence The document is a formal opinion from the nomination committee of the board regarding the qualifications of independent director candidates. It references relevant laws and regulations about director qualifications and independence, and concludes with a recommendation to the board. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, and no report publication. The content is clearly about board/management information, specifically about board nominations and qualifications. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and focused on management nomination, not a report or announcement of a report.
2025-01-07 Chinese
关于召开2025年第一次临时股东会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting of shareholders for 特一药业集团股份有限公司. It includes information about the meeting date, time, location, agenda items (such as election of independent directors), voting procedures (including cumulative voting and online voting), registration methods, and proxy forms. There are no financial statements or financial performance data included. The document is a formal announcement to shareholders about the meeting and how to participate and vote. It is not a report of the meeting results, nor is it a financial report or earnings release. Given the content and purpose, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual or Extraordinary General Meeting, including notices of meetings and related procedural information.
2025-01-07 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total funds used, and compliance with relevant regulations. The document does not contain full financial statements or comprehensive financial analysis but focuses solely on the share buyback activity. The length is relatively short (1423 characters), and the content is specific to share repurchase progress rather than a full report or earnings release. Therefore, it fits the category of Transaction in Own Shares (POS).
2025-01-02 Chinese
关于调整董事会、监事会换届计划及补选独立董事的提示性公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company about adjustments to the board of directors and supervisory board election plans, including the re-election of independent directors. It references regulatory guidance from the China Securities Regulatory Commission and discusses internal governance changes. There are no financial statements, earnings data, or detailed financial analysis present. The document is focused on management and board changes rather than financial results or reports. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2024-12-30 Chinese
关于签署募集资金监管协议之补充协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a supplementary agreement related to the supervision of raised funds (募集资金监管协议之补充协议). It details the background of the fundraising, the amount raised, the use of funds, and the signing of a supplementary agreement with banks and a securities company. The document is relatively short (1495 characters) and does not contain financial statements or detailed financial analysis. It is an update on financing activities and capital usage, specifically about the management and regulation of raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-12-30 Chinese
关于第五届董事会第二十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by 特一药业集团股份有限公司, detailing the approval of a proposal to use idle raised funds temporarily to supplement working capital. It includes meeting details, voting results, and references another announcement on the same topic. The document is short (989 characters) and does not contain financial statements or detailed financial data. It is a formal announcement of a board decision rather than a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG).
2024-12-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.